Purpose. The role of trastuzumab in adjuvant therapy for locally invasive breast cancer is discussed. Summary. Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of human epidermal growth factor receptor-2 (HER2). Currently, trastuzumab is indicated for use in HER2-positive patients with metastatic breast cancer. Because trastuzumab specifically targets a receptor that is overexpressed in tumor cells, it is less likely to cause the cytotoxic adverse effects of traditional chemotherapy. Cardiotoxicity has been a major concern, however. Several trials were started to evaluate trastuzumab in the adjuvant setting in patients diagnosed with earlystage breast cancer. The interim results of these trials have shown a promising effect of adjuvant therapy with trastuzumab in improving overall survival, disease-free survival, relapse-free survival, and distantdisease-free survival. Conclusion. The use of trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer can lead to increased survival. The appropriateness of trastuzumab therapy should be considered based on HER2 status, cost, and risk of toxicity.
C
ancer is one of the most common causes of death in the United States, causing almost one fourth of all deaths. 1 Breast cancer is the most commonly diagnosed cancer among women, with 211,240 new cases projected for 2005 in the United States, accounting for 32% of cancer diagnoses in women. Breast cancer is estimated to have been responsible for 40,140 deaths in 2005. While the rate for breast cancer has increased over the past 20 years, the death rate has been declining. Treatment and outcomes are influenced by the stage of cancer, which is determined by the size and number of tumors involved, lymph node involvement, and presence of metastases. The prognosis is favorable if the breast cancer is operable, with an overall survival (OS) of approximately 70% five years after diagnosis. 2 The chance of recurrence within five years is 30-35% if the cancer is node negative and 50-60% if node positive. Node-negative breast cancer may be termed high risk if it is estrogen-receptor (ER) negative, progestin-receptor (PR) negative, contains a tumor that is greater than 2 cm in diameter, or contains a tumor that is pathologically grade 2 or 3. 3 When breast cancer is operable, adjuvant chemotherapy is given after surgery or irradiation to decrease the chance of recurrence by killing cancer cells that may have migrated elsewhere in the body. Multiple chemotherapy regimens have been used for adjuvant treatment of breast cancer. Cyclophosphamide, methotrexate, and fluorouracil were traditionally used together for six months. Anthracyclines, such as doxorubicin and epirubicin, have been shown to increase survival and decrease recurrence and are now considered standard components of a regimen. 2 Various combinations may also include taxanes, such as paclitaxel and docetaxel, to increase survival. 4 In addition, due to the large number of women with breast cancer associated with up-regulated ERs, hormonal therapies are often used to negate estrogen-stimulated unregulated growth in the breast.
Trastuzumab overview
Trastuzumab (Herceptin, Genentech, Inc.) is a humanized monoclonal antibody that binds to the THERAPY UPDATES Trastuzumab extracellular domain of human epidermal growth factor receptor-2 (HER2).
5 HER2 is a protooncogene that can cause cellular differentiation and proliferation through tyrosine kinase activity and is overexpressed in about 20-25% of breast cancer tumor cells. Patients with HER2-positive breast cancer generally have a more aggressive disease and a poorer prognosis. Blocking HER2-stimulated growth of cancer cells is the general mechanism of action of trastuzumab; however, the complete mechanism of antitumor activity has not been fully characterized. Trastuzumab may cause down-regulation of the HER2-receptor and decreased signal transduction. 6 Also, it may cause antibody-dependent, cellmediated cytotoxicity. 6, 7 Trastuzumab has been shown to decrease angiogenesis through action at the vascular endothelial growth factor receptor in vitro. 8 Currently, trastuzumab is indicated for use in HER2-positive patients with metastatic breast cancer. 7 It has additive efficacy when used with paclitaxel, vinblastine, methotrexate, doxorubicin, or epirubicin. 9, 10 Vinorelbine, thiotepa, cisplatin, carboplatin, docetaxel, cyclophosphamide, and etoposide have a synergistic effect with trastuzumab. Trastuzumab is antagonized by concurrent use with fluorouracil. 10 Although very effective, the use of trastuzumab concurrently with doxorubin is not recommended due to cardiotoxicity. Liposomal doxorubicin and epirubicin are possible alternatives to doxorubicin that may cause less damage to the heart and are being investigated for use in combination with trastuzumab. 11, 12 Because trastuzumab specifically targets a receptor that is overexpressed in tumor cells, it is less likely to cause the cytotoxic adverse effects of traditional chemotherapy. When the drug is first infused, about 25-40% of patients will experience a mild infusion reaction characterized by fever and chills. 7, 13 This is dose related and can be minimized with diphenhydramine and acetaminophen. A very small percentage of people, about 0.3%, will experience a serious reaction, including bronchospasm, hypotension, and dyspnea. 7 Minor adverse effects, including pain, asthenia, headache, nausea, diarrhea, constipation, rash, flulike symptoms, anxiety, insomnia, and rhinitis, were reported in over 10% of patients in one trial using trastuzumab as monotherapy for unresponsive metastatic breast cancer. 14 Cytopenias were rare with trastuzumab alone.
Cardiotoxicity has been a major concern with trastuzumab and requires additional screening for cardiac dysfunction. Many patients in this population are already at risk due to previous anthracycline therapy and age. 5 When used as monotherapy, trastuzumab has a 1-7% frequency of inducing cardiac dysfunction, specifically congestive heart failure (CHF) and decreased left ventricular ejection fraction (LVEF). 5, 7 The rate of cardiac dysfunction is about 4-13% when trastuzumab is used with taxanes and rises to 19-27% when used with doxorubicin and cyclophosphamide. 5 The mechanism of this phenomenon is not known, but possibly HER2-receptors located in cardiac tissue play a role in differentiation and survival. 5 To decrease the likelihood of adverse cardiac events, trastuzumab is contraindicated in patients with decreased cardiac function and should be discontinued if patients develop symptoms of decline in cardiac function.
Different guidelines have been proposed regarding how to monitor cardiac function and when to withhold or discontinue therapy. Multiple gated acquisition is often used to identify drops in LVEF, while echocardiography may be useful in ruling out alternative causes of decreased LVEF. For metastatic breast cancer patients, weekly monitoring of heart rate and body weight has been proposed, with appropriate follow-up if either value increases drastically. This guideline suggests stopping therapy if the patient is asymptomatic and LVEF falls at least 20 percentage points to less than 40% or LVEF is less than 30%. If the patient had symptomatic cardiac dysfunction, it has been proposed that trastuzumab be withheld if the LVEF falls at least 10 percentage points to less than 50%. 15 Two trials presented in this article used the following guidelines: cardiac function should be monitored routinely in patients on trastuzumab, and the drug should be withheld if there is a 15% decrease in LVEF or at least a 10% decrease in LVEF and LVEF falls at least 1% below the lower limit of normal (LLN). When the drug is withheld, LVEF can be reassessed in four weeks. Trastuzumab should be permanently discontinued if it needs to be withheld for two consecutive doses or three total doses. These trials and many similar trials monitored cardiac function every three months.
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Trastuzumab as adjuvant therapy
Once trastuzumab had proven successful in improving survival outcomes in metastatic breast cancer, several trials were started to evaluate trastuzumab in the adjuvant setting. Four large-scale, randomized, multicenter, Phase III trials are currently evaluating the safety and efficacy of trastuzumab for use as adjuvant therapy in breast cancer. [16] [17] [18] A combined interim analysis of two of the trials, the North Central Cancer Treatment Group Intergroup trial (N9831) and the National Surgical Adjuvant Breast and Bowel Project trial (B-31), was recently published. 16 The results from the Herceptin Adjuvant (HERA) trial were also recently reported. 17 The fourth trial, Breast Cancer International Research Group (BCIRG) trial 006, is still under way. 18 A combined analysis of
THERAPY UPDATES Trastuzumab
N9831 and B-31 was possible because both the design and patient selection of those two trials were very similar. 16 All patients entering the trials were required to be immunohistocompatibility 3+ or fluorescence in situ hybrid positive; to have invasive breast cancer; to have had a prior lumpectomy, mastectomy, or lymph node dissection; and to have normal LVEF and normal hematologic, hepatic, and renal functions. Exclusion criteria for both trials consisted of previous anthracycline or taxane therapy, a history of significant peripheral neuropathy, a history of cardiac disease, or locally advanced or distant disease. The patients recruited for B-31 were exclusively node positive. N9831 included node-positive and high-risk node-negative patients. Node-negative women were considered high risk if they were ER negative with a tumor at least 1 cm in diameter or ER positive with a tumor at least 2 cm in diameter. 16 Characteristics of the patients in both trials are listed in Table 1 .
The designs for N9831 and B-31 are shown in Figures 1 and 2 , respectively. While B-31 compared trastuzumab with no trastuzumab, N9831 was designed with an additional group receiving trastuzumab after the paclitaxel regimen was completed to compare concurrently administered trastuzumab with sequentially administered trastuzumab. 16 For the combined interim analysis, only patients from groups A and C were included from N9831, because B-31 did not have a group comparable to group B. Both trials withheld trastuzumab if a patient had symptoms of cardiac dysfunction. As mentioned previously, trastuzumab was withheld in asymptomatic patients if LVEF decreased more than 15% or if it decreased more than 10% and was at least 1% below the LLN. 16 If the dose was withheld, LVEF was reassessed in four weeks. Trastuzumab was permanently discontinued if it had to be with withheld for two consecutive or a total of three doses.
A total of 3676 women were included in the analysis. The final endpoint for definitive analysis of the two trials was 710 disease-freesurvival (DFS) events. 16 The interim analysis was carried out once 355 events occurred, with the intention of stopping the trials if equivalency was rejected with a significance level of 2p = 0.001. Intention to treat was maintained in both trials and the analysis. DFS was the primary endpoint; OS and time to first distant recurrence (TTDR) were secondary endpoints. The average follow-up at the point of analysis was 2 years (2.4 years for B-31 and 1.5 years for N9831).
Following analysis of the interim results, both trials were closed because equivalency was rejected in favor of trastuzumab and the predetermined significance criteria were met. 16 The combined DFS almost four years after randomization was 85% for patients in the trastuzumab groups and 67% for patients in the nontrastuzumab groups (hazard ratio [HR] = 0.48, 2p = 3 × 10 -12 ). This was significant for all subgroups regardless of age, hormone-receptor status, and tumor size. It was not significant for node-negative patients, as the number of node-negative patients in the two trials was probably too small to detect a significant difference. OS was 91% for those on trastuzumab and 87% for those not Figure 1 . N9831 trial design scheme. 16 Radiation therapy or tamoxifen or both were allowed after six months if needed.
on trastuzumab (HR = 0.67, 2p = 0.015). The TTDR was measured as the percentage without distant recurrence and was 90% for patients treated with trastuzumab and 74% for those not treated with trastuzumab (HR = 0.47, 2p = 8 × 10 -10 ). Cardiac adverse events were analyzed for each trial. Nine months after randomization in N9831, 12 of 542 (2.2%) patients in group B and 20 of 602 (3.3%) patients in group C experienced a cardiac event, compared with 0 of 544 patients in group A. 16 Nineteen of the 20 patients with cardiac events in group C experienced CHF, with one death. Three years after doxorubicin and cyclophosphamide therapy was completed in B-31, the cumulative incidence of cardiac events was 4% with trastuzumab, compared with 0.8% without trastuzumab. 16 The trastuzumab group had 31 patients who developed CHF, with no deaths due to CHF. Among patients not on trastuzumab, 4 patients developed CHF and one died of it. Age and postdoxorubicin and cyclophosphamide therapy LVEF were independent predictors of trastuzumab-associated CHF. The HERA trial is the third randomized trial. 17 Five thousand ninety patients are enrolled in this international trial. All enrolled patients have HER2-positive invasive breast cancer, are either node positive or node negative with a tumor at least 1 cm in diameter, have completed at least four cycles of adjuvant or neoadjuvant chemotherapy, have a baseline LVEF of at least 55%, and have known hormone-receptor status. Patient demographics for this trial are shown in Table 2 .
All women had surgery plus adjuvant or neoadjuvant chemotherapy and possibly radiation therapy before randomization. This trial was less rigorous than the previous two trials because different adjuvant regimens were allowed. Patients were stratified based on adjuvant chemotherapy, nodal status, hormone-receptor status, endocrine therapy, age, and region. They were then randomized and either given trastuzumab for one or two years or observed following other chemotherapy treatments. Patients in both trastuzumab groups of this trial were given trastuzumab following other chemotherapy, not concurrently. The design of this trial is shown in Figure 3 .
As in the other trials, the primary endpoint was DFS between either trastuzumab group and the observation group. 17 Secondary endpoints The safety endpoint was a 4% absolute increase in cardiac events compared with the observation group. Most patients in this trial were node positive; however, a larger fraction, about one third, were node negative. Also, most of the patients in this study did not receive a taxane. 17 The results of the HERA trial were similar to the combined analysis of B-31 and N9831. Only patients in groups A and C were compared (trastuzumab for one year versus observation) at the interim analysis. Two years after randomization, the DFS was 85.8% in group A and 77.4% in group C (HR = 0.54, p < 0.0001). This result was consistent in most subgroups, including nodenegative patients. OS in the trastuzumab group was 96%, versus 95% in the observation group (HR = 0.76, p = 0.26). The RFS was 87.2% in group A, versus 78.6% in group C (HR = 0.50, p < 0.0001), and the DDFS was 89.7% in group A, versus 81.8% in group C (HR = 0.51, p < 0.0001). About 8% of patients in the trastuzumab group experienced grade 3 or 4 adverse effects, compared with 4.3% in the observation group. The treatment withdrawal rate in the trastuzumab group was 8.5%, with 6% being for safety reasons.
Cardiotoxicity was also assessed, and 7.1% of patients in the trastuzumab group and 2.2% of patients in the observation group experienced at least a 10-percentage-point decrease in LVEF concurrently with an LVEF of less than 50%; 0.5% of patients had symptomatic CHF that was diagnosed as being New York Heart Association function class III or IV by a cardiologist. The death rate for cardiotoxicity was 0% in the trastuzumab group and 0.1% in the observation group. 17 The fourth trial is being conducted by the BCIRG. BCIRG 006 is another multicenter, randomized, Phase III trial testing the addition of trastuzumab to adjuvant therapy in women with either node-positive or highrisk node-negative operable breast cancer. This study includes 3150 women randomized to one of three groups: cyclophosphamide and doxorubicin followed by docetaxel, cyclophosphamide and doxorubicin followed by docetaxel and trastuzumab, and docetaxel, carboplatin, and trastuzumab given concurrently. Thus, one objective of this study is to determine the safety and efficacy of trastuzumab without prior anthracycline therapy. The primary endpoint of this trial is DFS. OS, toxicity, and quality of life are secondary endpoints. An interim analysis of this trial is planned for the first quarter of 2006.
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Study limitations
Limitations exist regarding interpretation of these studies. Longer follow-up may be needed to assess cardiac toxicity in these trials, as the long-term implications of a mild decline in cardiac function due to trastuzumab are unclear. The decision to combine N9831 and B-31 for the interim analysis was made after the trials were designed and initiated. 16 Finally, these trials were not blinded. While these limitations exist, the fact that the survival endpoints were drastically affected by the time of the interim analysis is a strong indicator that trastuzumab has a place as part of adjuvant chemotherapy in HER2-positive women.
Clinical and economic considerations
Evidence supports the adjuvant use of trastuzumab in HER2-positive women with node-positive breast cancer and normal cardiac function. Further analysis of the current trials and possibly new trial designs will be necessary before the optimum duration of therapy and concurrent regimens are known. Additionally, further analysis or trials with more node-negative patients may be needed before treatment in this population can be evaluated.
Trastuzumab, like any other drug, is associated with risks and benefits that need to be weighed for each individual before the decision to use the drug can be made. It should not be used in women with compromised cardiac function, and cardiac function should be monitored periodically for all patients on the drug. The implications of cardiac toxicity are different in adjuvant therapy versus metastatic therapy. Patients with metastatic disease have a significantly shorter life expectancy, and the majority will probably die of cancer before heart failure. In the adjuvant setting, however, the risks and benefits of trastuzumab will have to be considered over a longer lifespan. Additionally, there is a risk of a lifethreatening infusion reaction in all patients, and trastuzumab should be infused with caution, especially with the first dose.
The average wholesale price of trastuzumab is $2,928.89 for 440 mg. 19 For a 70-kg woman, each 2-mg/kg dose would cost about $1,000, and a yearly regimen would cost about $50,000. While about 5 to 10 women per 100,000 population have metastatic breast cancer, between 90 and 100 per 100,000 have localized breast cancer, and around 40 per 100,000 have regional breast cancer. 20 Thus, with a U.S. female population of over 143,000,000, about 7,000 to 14,000 women may have metastatic breast cancer, about 130,000 to 140,000 have localized breast cancer, and about 60,000 have regional breast cancer. 21 If trastuzumab is to be a standard part of an adjuvant regimen for HER2-positive patients, the cost of treating this population could increase by almost $1 billion for trastuzumab treatment alone. Additional costs for treating heart failure would also be incurred.
The interim results presented at the ASCO meeting regarding the use The use of trastuzumab in the adjuvant setting is associated with significantly increased DFS, RFS, and DDFS. As a result of the efficacy of trastuzumab supported by the combined interim analysis, N9831 and B-31 have been closed. The effects of trastuzumab on OS were favorable, if not significantly increased, in all trials. Although a higher fraction of patients in all trastuzumab groups experienced decreases in LVEF and cardiac events, the death rate from CHF was comparable to that of patients who did not receive trastuzumab. Longer follow-up should give more information regarding the reversibility of these decreases in LVEF, risks of cardiac events, and long-term risks.
Currently, trastuzumab does not have approval from FDA for use in adjuvant treatment for breast cancer; however, it is currently under review, and an expanded indication is expected in 2006. Due to the large number of women with operable breast cancer and the relatively large proportion who are HER2 positive, the decision to make this treatment part of the standard of care is financially significant. Individually, the appropriateness of the therapy will have to be considered based on HER2 status, costs, and toxicities.
Conclusion
The use of trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer can lead to increased survival. The appropriateness of trastuzumab therapy should be considered based on HER2 status, cost, and risk of toxicity.
